Penumbra (PEN) Net Income towards Common Stockholders Growth (3y) (2017 - 2026)
Penumbra (PEN) Net Income towards Common Stockholders Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.63 Bn | 194.02 Bn | 7.27 Bn | -12.28% |
| 2 | Stryker | 127.42 Bn | 123.95 Bn | 4.50 Bn | 20.02% |
| 3 | Medtronic | 118.97 Bn | 109.75 Bn | 6.41 Bn | 1.93% |
| 4 | Boston Scientific | 73.39 Bn | 72.85 Bn | 3.85 Bn | 51.47% |
| 5 | Edwards Lifesciences | 51.97 Bn | 47.72 Bn | 1.35 Bn | -7.83% |
| 6 | Dexcom | 34.32 Bn | 32.37 Bn | 830.00 Mn | 29.05% |
| 7 | GE HealthCare Technologies | 33.76 Bn | 31.65 Bn | 2.18 Bn | 11.15% |
| 8 | Koninklijke Philips | 26.35 Bn | 23.03 Bn | 4.55 Bn | 1,825.47% |
| 9 | Steris | 23.04 Bn | 22.56 Bn | 684.20 Mn | 17.54% |
| 10 | Penumbra | 12.78 Bn | 12.12 Bn | 264.94 Mn | 22.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 22.47% |
| Mar 31, 2026 | 56.13% |
| Dec 31, 2025 | 130.28% |
| Sep 30, 2025 | 181.01% |
| Jun 30, 2025 | 142.66% |
| Mar 31, 2025 | 691.84% |
| Dec 31, 2024 | 49.89% |
| Sep 30, 2024 | 54.26% |
| Jun 30, 2024 | -109.95% |
| Mar 31, 2024 | 0.23% |
| Dec 31, 2023 | 174.13% |
| Sep 30, 2023 | 43.14% |
| Jun 30, 2023 | 51.36% |
| Mar 31, 2023 | 112.84% |
| Dec 31, 2022 | -25.30% |
| Sep 30, 2022 | -30.19% |
| Jun 30, 2022 | -30.59% |
| Mar 31, 2022 | -80.38% |
| Dec 31, 2021 | -79.78% |
| Sep 30, 2021 | 33.39% |